GSK and Eligo Bioscience targets skin microbiome in €185m acne deal 21-Jan-2021 By Will Chu British pharma company GlaxoSmithKline (GSK) are to pair up with Eligo Bioscience in a deal potentially worth €185m ($224m) that sees the firms target the microbiome to reduce the risk of developing acne.